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Background. Mannose-binding lectin (MBL) plays a key role in the activation of the lectin-complement pathway
of innate immunity, and its deﬁciency has been linked with several acute infections. However, its role in predisposing
to, or modulating disease severity in, Clostridium difﬁcile infection (CDI) has not been investigated.
Methods. We prospectively recruited 308 CDI case patients and 145 control patients with antibiotic-associated
diarrhea (AAD). CDI outcome measures were disease severity, duration of symptoms, 30-day mortality, and 90-day
recurrence. Serum concentrations of MBL were determined using a commercial enzyme-linked immunosorbent
assay transferred to an electrochemiluminescence–based platform. MBL2 polymorphisms were typed using a com-
bination of pyrosequencing and TaqMan genotyping assays.
Results. The frequency of theMBL2 genetic variants was similar to that reported in other white populations. MBL
serum concentrations in CDI and AAD subjects were determined by MBL2 exonic variants B, C, and D and the hap-
lotypes (LYPB, LYQC, and HYPD). There was no difference in either MBL concentrations or genotypes between cases
and controls. MBL concentration, but not genotype, was a determinant of CDI recurrence (odds ratios, 3.18 [95% con-
ﬁdence interval {CI}, 1.40–7.24] and 2.61 [95% CI, 1.35–5.04] at the <50 ng/mL and <100 ng/mL cutoff points, respec-
tively; P < .001). However, neither MBL concentration nor MBL2 genotype was linked with the other CDI outcomes.
Conclusions. Serum MBL concentration did not differentiate between CDI cases and AAD controls, but among
CDI cases, MBL concentration, but not genotype, was associated with CDI recurrence, indicating that MBL acts as a
modulator of disease, rather than a predisposing factor.
Keywords. Clostridium difﬁcile; CDI; MBL; disease recurrence.
The initiation and propagation of inﬂammatory cas-
cades is an essential housekeeping property of the
innate immune response during infections. Mannose-
binding lectin (MBL) activates the lectin-complement
pathway of innate immunity through binding to repet-
itive sugar arrays on microbial surfaces [1]. MBL is also
a potent regulator of inﬂammatory pathways: it can
modulate phagocyte interaction with mucosal organ-
isms at the site of infection [2], and interacts with
other components of the innate immune system such
as Toll-like receptors [3].
Low MBL concentrations have been associated with
increased susceptibility to infections in both animal
models and humans [4, 5], as well as with poor disease
prognosis [1]. The modulation of disease severity is
Received 17 June 2014; accepted 9 August 2014; electronically published 28 Au-
gust 2014.
aA. S. and F. M. contributed equally to this work.
Correspondence: Fabio Miyajima, PhD, Molecular and Clinical Pharmacology,
University of Liverpool, Wolfson Centre for Personalised Medicine, 1-5 Brownlow
St, Liverpool, Merseyside L69 3GL, UK (fabio@liv.ac.uk).
Clinical Infectious Diseases® 2014;59(10):1429–36
© The Author 2014. Published by Oxford University Press on behalf of the Infectious
DiseasesSocietyofAmerica. This isanOpenAccessarticle distributedunder the terms
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any
medium, provided the original work is properly cited.
DOI: 10.1093/cid/ciu666
Mannose-Binding Lectin and Clostridium difﬁcile Infection • CID 2014:59 (15 November) • 1429
 by guest on M
ay 29, 2015
http://cid.oxfordjournals.org/
D
ow
nloaded from
 
partly thought to be through a complex, dose-dependent
inﬂuence on cytokine production [6]. Serum MBL concentra-
tions range from negligible to as high as 10 000 ng/mL [7–9];
this varies with ethnicity and with the screening method
adopted [10].
MBL secretion in humans is dependent on theMBL2 genetic
architecture [11, 12]. To date, 57 genetic variants have been
identiﬁed within the entire MBL2 gene (dbSNP, build 140,
NCBI), with only 6 of them known to affect secretion and/or
function of the encoded protein (Figure 1) [8, 13]. The mutated
alleles B, C, or D are collectively termed O and their correspon-
dent wild-type alleles are jointly referred to as variant A, with
the presence of any given O variant (in either the heterozygous
or homozygous state) resulting in MBL deﬁciency [8, 13]. The
existence of strong linkage disequilibrium (LD) between the
promoter and structural gene variants means that only 7 com-
mon haplotypes (out of a possible 64), which may affect serum
concentrations, have been described: HYPA, LYQA, LYPA,
LXPA, HYPD, LYPB, and LYQC [14, 15]. HYPD, LYPB, and
LYQC lead to the production of unstable ligands with shorter
half-lives that are easily degraded to lower oligomeric forms.
Studies that have evaluated both genetic mutations and serum
concentrations in white populations are summarized in Supple-
mentary Table 1.
Clostridium difﬁcile is an opportunistic spore-forming bacte-
rium that can effectively colonize the intestinal tract following
antibiotic-driven dysbiosis. Clostridium difﬁcile infection
(CDI) is the result of intense colonic inﬂammation caused by
the release of potent enterotoxins. Research into host biomark-
ers for CDI has focused on mediators of inﬂammation in the
gut, such as fecal interleukin 8 [16], lactoferrin [16], and cal-
protectin [17], and linked them with disease severity [16, 18].
More recently, both serum interleukin 23 and procalcitonin
have also been proposed as potential biomarkers for CDI se-
verity [19, 20]. However, the role of these biomarkers in the
stratiﬁcation of problematic CDI patients remains unclear,
and thus remains an important area of research. Additionally,
several clinical prediction rules have been proposed for the eval-
uation of CDI outcomes [21–23], but none have gained wide-
spread clinical acceptance.
To date, there have been no studies on the role of either MBL
levels or MBL2 genetic variants with CDI, possibly because MBL
is not thought to bind to the surface of C. difﬁcile [24]. However,
there is growing evidence for an association between MBL and
major modulators of inﬂammation, such as Toll-like receptors
and C-reactive protein (CRP), both of which have been associated
with CDI [25, 26]. Therefore, we sought to investigate the role of
MBL in a prospective cohort of CDI cases and inpatient controls.
Figure 1. Schematic representation of the majorMBL2 isoform and genetic polymorphisms. Polymorphisms responsible for the haplotypes that ultimately
determine mannose-binding lectin (MBL) expression levels are indicated by the red arrows. *In this study, rs10556764 (6-bp deletion) was used as a proxy
single-nucleotide polymorphism for rs7095891.
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METHODS
Cohort
A cohort of 453 inpatients was consecutively recruited from a
large hospital setting in Merseyside, United Kingdom. Patients
were eligible for inclusion if they had healthcare-associated di-
arrhea (deﬁned as ≥3 liquid stools passed in the 24 hours pre-
ceding assessment), an onset after being in hospital for >48
hours, and recent exposure to either antimicrobials and/or pro-
ton pump inhibitors (PPIs). Using criteria previously described
[27], 308 patients with CDI (cases) and 145 control patients
with antibiotic-associated diarrhea (AAD) were classiﬁed
based on toxin enzyme-linked immunosorbent assay (ELISA)
test (TOX A/B II, Techlab, Blacksburg, Virginia), microbiological
culture, and clinical diagnosis made by independent clinicians.
Polymerase chain reaction (PCR) ribotyping and multiplex
PCR were performed to determine strains types and the toxigenic
nature of the isolates [28].
Blood and fecal specimens were collected from patients at
study entry, of whom 98% were white. Relevant information
on demographics, admission, and clinical history was collected
for each patient. Ethical approval was obtained from the Liver-
pool Research Ethics Committee (reference number 08/H1005/
32), and each patient provided written informed consent prior
to recruitment.
Deﬁnition of Outcomes
Cases and controls were deﬁned as described above. The se-
verity of CDI symptoms was assessed at baseline by research
nurses using the guidelines proposed by Public Health England
[29], which we adjusted to incorporate a more stringent white
blood cell count cutoff of >20 × 109/L while also replacing acute
rising creatinine with an estimated glomerular ﬁltration rate of
<30 mL/min/1.73 m2 at the time of diagnosis. Duration of
symptoms was recorded from the date of onset of symptoms
and then dichotomized into episodes lasting ≥10 or <10 days.
All-cause mortality was actively monitored for a period of 30
days from diagnosis, and recurrent CDI was deﬁned as the de-
velopment of subsequent CDI episodes up to a period of 90 days
post-diagnosis of the initial episode. If the patient was dis-
charged from hospital prior to ﬁnal follow-up, we attempted
in every case to obtain data from the hospital, general practi-
tioner, or patient (the latter by a telephone call).
Determination of MBL Serum Concentrations
A commercially available in vitro diagnostic ELISA kit (Sanquin
Blood Supply, Amsterdam, the Netherlands) was transferred
onto the Meso Scale Discovery electrochemiluminescence
(ECL)–based platform, undergoing appropriate optimization
prior to use. The MBL kit control was used across all plates to
determine interplate variability and a subsequent correction
factor used for each plate. Final minimum detection level
(lower limit of detection [LLOD]) and minimum quantiﬁcation
level (lower limit of quantiﬁcation [LLOQ]) were calculated by
taking the mean values across all plates. The mean LLOD and
LLOQ across all plates were 11.3 and 11.0 ng/mL, respectively,
with overall median values of 491.9 ng/mL among controls and
361.8 ng/mL in cases. Signal values ranged from only 50 to 500
ECL units, which denotes a compressed signal range inherent
with the assay. Because this may have potentially limited dis-
crimination of the quantitative values, data were subject to bi-
nary categorization based on 3 previously used deﬁciency
cutoffs: 50, 100, and 500 ng/mL [30–32].
Determination of MBL2 Variants
A total of 9 variants lying in the promoter and exon 1 were
typed (Figure 1) by either pyrosequencing (PyroMark Q96 cus-
tom assays, Qiagen; rs36014597, rs7084554, rs1800451,
rs1800450, rs5030737, and rs10556764) or TaqMan SNP geno-
typing (Applied Biosystems; rs7096206, rs11003125, and
rs11003123). The variants rs1800451 (C), rs1800450 (B),
rs5030737 (D), rs7096206 (X/Y), and rs11003125 (H/L) were
used for haplotype determination, and rs10556764, a 6-bp
Ins/Del in complete LD with rs7095891 (P/Q), was used as
a proxy. Another recognized tagging marker for P/Q
(rs11003123) was independently typed to evaluate the accuracy
of the pyrosequencing assays.
Table 1. Demographics of Patients With Clostridium difﬁcile
Infection and Antibiotic-Associated Diarrhea
Patient’s Characteristics
CDI Cases
(n = 308)
AAD Controls
(n = 145)
Female sex 177/308 (57) 81/142 (57)
Age, y, mean (SD) 70.1 (16.4) 65.0 (17.6)
BMI, kg/m2, mean (SD) 24.6 (6.8) 26.9 (6.9)
Presence of immunosuppression 52/307 (17) 35/144 (24)
Presence of renal comorbidity 157/307 (51) 82/144 (57)
Presence of diabetes 58/307 (19) 39/144 (27)
Charlson comorbidity score,
median (IQR)
1.0 (0.0–2.0) 1.0 (0.0–2.0)
Time delay (testing/recruitment),
median (IQR)
3.0 (2.0–4.0) 2.0 (2.0–3.0)
Clinical parameters
Duration of symptoms ≥10 d 175/290 (60)a 32/134 (24)
All-cause mortality within 30 d 26/305 (9) 5/142 (4)
All-cause mortality within 1 y 95/271 (35)b 25/141 (18)
Disease severity at baseline 127/308 (41) . . .
Recurrence within 90 d 83/220 (38) . . .
Data are presented as No. (%) unless otherwise specified. Differences
between case and control groups were found to be statistically significant:
a P < .0001; b P < .001.
Abbreviations: AAD, antibiotic-associated diarrhea; BMI, body mass index;
CDI, Clostridium difficile infection; IQR, interquartile range; SD, standard
deviation.
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Pyrosequencing
PCR optimization was conducted using 20 ng of genomic DNA
and temperature gradients following standard guidelines. Opti-
mized products were run on a PyroMark Q96 ID following the
recommended assay protocol. Repeat samples and blanks were
included for quality control purposes, and data were analyzed
using PyroMark Q96 software (version 2.5.8).
TaqMan Genotyping
Reactions consisted of 20 ng genomic DNA, 1× TaqMan SNP
genotyping assays, run on an Applied Biosystems HT 7900
Fast Real-time PCR system (Applied Biosystems) using stan-
dard cycling conditions. Repeat samples and blanks were incor-
porated for quality control purposes, and results analyzed using
SDS software (version 2.2).
Statistical Analysis
Median MBL serum concentrations were compared for individ-
ual SNPs and haplotypes by the Mann–Whitney U test, then
subjected to stratiﬁcation based upon previously used 2-marker
grouping proﬁles termed high- (YA/YA and XA/YA), interme-
diate- (XA/XA and YA/YO), and low-expressing (XA/YO & YO/
YO) genotypes [32, 33].
The effect of bothMBL2 genetics (based on stratiﬁed expres-
sion genotypes) and serum MBL concentrations (based upon
deﬁciency cutoffs) were individually taken forward for case-
control comparison and subgroup analysis of cases. For the lat-
ter, this included logistic regression for the following outcome
measures: (1) severity of disease, (2) duration of symptoms ≥10
days, (3) 90-day recurrence, and (4) 30-day mortality. Covari-
ates including demographic variables, the presence of PCR
ribotype 027/NAP/BI1, and potential confounders (immuno-
suppressive therapy, renal disease, and diabetes; score on Charl-
son comorbidity index; and time delay between sample testing
positive and recruitment) were individually assessed. Severity of
disease was assessed both as a CDI outcome and as a baseline
predictor for the other outcomemeasures. Statistically signiﬁcant
covariates were added to the ﬁnal regression model to produce
adjusted P values, odds ratios (ORs), and 95% conﬁdence inter-
vals (CIs). All analyses were carried out using SPSS (version 20).
Power calculations were simulated using nQuery Advisor +
nTerim (version 2.0). This showed that the power a posteriori
was ≥99% for the majority of analyses. However, for analysis
of 30-day mortality and disease severity at baseline, power
was lower (67% and 75%, respectively; Supplementary Table 2).
RESULTS
Patient Demographics
CDI cases and AAD controls were demographically comparable
(Table 1). However, mortality at 1 year (35% vs 18%; P < .001)
and duration of diarrhea symptoms (≥10 days 60% vs 24%;
P < .0001) were signiﬁcantly greater among CDI cases. In rela-
tion to medication history, 9% (28/308) and 1% (2/145) of CDI
cases and AAD controls had prior exposure to PPIs but not an-
tibiotics within 90 days of the development of CDI, respectively,
with 58% (180/308) and 54% (79/145) exposed to both an an-
tibiotic and a PPI. Of CDI cases, 41% (127/308) had severe dis-
ease and 38% (83/220) experienced recurrence within 90 days.
Twenty-eight CDI cases, who had not experienced any recur-
rence of symptoms but died within the 90-day follow-up period,
could not be included in our analysis of recurrence.
Relationship of Genotype With Serum MBL Concentrations
Of the 9 variants typed in the CDI cases and AAD controls, 3
were excluded: 1 SNP (rs7084554) deviated from Hardy-
Weinberg equilibrium (<0.001); rs11003123 was deemed redun-
dant due to complete LD with the Ins/Del polymorphism
(rs10556764); and rs36014597 was also in complete LD with
both rs10556764 and rs11003123. Of the 6 polymorphisms ana-
lyzed, the genotyping success rate was ≥95%. Their minor allele
frequencies were in line with those reported in the literature (Sup-
plementary Table 3). For both groups, 7 common haplotypes
were derived from the 6 polymorphisms (Supplementary
Table 2. Mannose-Binding Lectin (MBL) Serum Concentrations Across MBL2 Haplotypes in Patients With Clostridium difﬁcile Infection
and Antibiotic-Associated Diarrhea
Haplotype HYPA LYPA LYQA LXPA HYPD LYPB LYQC
Presence of haplotype
No. (% frequency) 213 (29) 44 (6) 143 (19) 170 (23) 55 (7) 108 (15) 11 (1)
Median, ng/mL (range) 612 (17–3981) 587 (0–2500) 529 (0–3981) 428 (0–2968) 157 (0–815) 73 (0–637) 48 (0–492)
Absence of haplotype
No. (% frequency) 198 (9) 367 (17) 268 (13) 241 (11) 356 (17) 303 (14) 400 (19)
Median: absence, ng/mL (range) 171 (0–2374) 388 (0–3981) 324 (0–2968) 377 (0–3981) 484 (0–3981) 568 (0–3981) 420 (0–3981)
P valuea <.001 .04 <.001 .34 <.001 <.001 .001
a P values were calculated using a Mann–Whitney test comparing mannose-binding lectin serum concentrations against the presence/absence of each individual
haplotype.
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Figure 1), which is consistent with other previous studies in white
populations (Table 2) [9, 34].
Presence of the mutant allele for all individual MBL2 variants
had a signiﬁcant inﬂuence on serum MBL concentration across
all patients, except for the X allele encoded by rs7096206 (P = .30;
Supplementary Table 3). All the assembledMBL2 haplotypes also
signiﬁcantly impacted on serum concentrations, except for hap-
lotype LXPA where there was no difference compared with the
overall median value (P = .34; Table 2). Genotypic and haplotypic
analyses demonstrated that the presence of a variant allele for any
of the 3 exonic variants (rs1800451, rs1800450, and rs5030737)
were the major contributing factors for lower MBL concentra-
tions (Table 2 and Supplementary Table 3).
Patients with high-expressing genotypes had a median serum
MBL concentration of 714 ng/mL, compared with 190 ng/mL
with intermediate-expressing genotypes, and 32 ng/mL with
low-expressing genotypes (P < .001; Table 3; Figure 2A). The
contribution of the X allele, seemingly insigniﬁcant when eval-
uated on an individual basis (Supplementary Table 3), became
apparent with a gradual decrease when compared with the
equivalent genotypes containing the Y allele in the rank
order: XA/YA < YA/YA, XA/XA < XA/YA, and XA/YO < YA/
YO (Table 3; Figure 2B).
MBL Deﬁciency Cutoff Points in Relation to Haplotype Groups
In total 59 (13%), 93 (21%), and 258 (58%) patients had serum
MBL concentrations below 50, 100, and 500 ng/mL, respectively.
When these data were compared with the “expressing” genotype
groups, 78% (42/54) and 68% (59/87) of those with concentra-
tions <50 ng/mL and <100 ng/mL, respectively, were low expres-
sors, compared with 28% (66/236) of those with a concentration
<500 ng/mL (Supplementary Table 4). The corresponding ﬁgures
for high expressors were 4% (2/54), 6% (5/87), and 30% (70/236),
respectively. Similarly, 96% (52/54) and 93% (81/87) of those
with concentrations <50 ng/mL and <100 ng/mL, respectively,
carried the deﬁcient (O) haplotypes, compared with 65% (153/
236) of those with a concentration <500 ng/mL (Supplementary
Table 4). Based on the results above, only the 50 and 100 ng/mL
cutoffs were taken forward for further analysis, which is consis-
tent with previous literature [30, 31].
Comparison of MBL Levels Versus CDI Disease Outcomes
Serum MBL concentrations are shown in Supplementary
Table 5. Analysis using both <50 ng/mL and <100 ng/mL as
Table 3. Median Serum Mannose-Binding Lectin Concentrations
Across Previously Deﬁned Expression Genotype Groupsa
MBL Expression
Group Genotype No.
Median,
ng/mL
Combined
Median, ng/mL
High YA/YA 124 854 714
XA/YA 113 561
Intermediate XA/XA 16 270 190
YA/YO 91 175
Low XA/YO 41 32 32
YO/YO 26 31
Abbreviation: MBL, mannose-binding lectin.
a Expression groups defined according to Eisen et al [32].
Figure 2. Median serum mannose-binding lectin (MBL) concentrations in relation to 3-tier grouping based on proposed expression proﬁles (A) and in-
dividual genotypic groups within proposed expression proﬁles (B). Median serum MBL concentrations were determined across previously deﬁned expression
proﬁles: high (YA/YA and XA/YA), intermediate (XA/XA and YA/YA), and low (XA/YO and YO/YO). Median levels were also determined for the 6 individual
genotypic groups across all expression proﬁles. Abbreviation: MBL, mannose-binding lectin.
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cutoff points to signify deﬁciency identiﬁed no signiﬁcant dif-
ferences between CDI cases and AAD controls (P = .79 and
P = .09, respectively) (Table 4). Evaluation of the clinical out-
comes in CDI cases showed a signiﬁcant association with CDI
recurrence (P < .01 for both; Table 4) with ORs of 3.18 and 2.61
at the <50 ng/mL and <100 ng/mL cutoff points, respectively.
No association was identiﬁed with any of the other outcomes
including prolonged symptoms, 30-day mortality, and disease
severity at baseline (Table 4). Despite the strong correlation ob-
served between genotypes/haplotypes and serum MBL concen-
trations in this cohort, no signiﬁcant associations were
identiﬁed between high-, intermediate-, and low-expressing ge-
notypes and CDI disease outcomes (Supplementary Table 6).
There was an inverse correlation between MBL and CRP
serum concentrations (R2 = −0.16, P = .001; Supplementary
Figure 2). No signiﬁcant correlation was identiﬁed with white
cell count (R2 =−0.04, P = .44).
DISCUSSION
Studies evaluating the role of MBL in infectious and immune dis-
eases have focused on either genotype, phenotype, or occasionally
on both parameters. The latter approach is preferred as it
can show discordance between genotype and phenotype. This
study is one of the larger disease-related studies concurrently in-
vestigating both genotypic/haplotypic variants and serum con-
centrations in a white population (Supplementary Table 1) and
is the ﬁrst to demonstrate an association between serum MBL
concentrations, but not genotype, and recurrence of CDI within
90 days using two distinct cutoff values for MBL deﬁciency.
The mechanistic basis of the association is unclear. With other
bacterial and viral infections, MBL is thought to be capable of
binding to the cell surfaces of invasive pathogens, thereby stimu-
lating a downstream immune response. However, this does not
seem to be the case with C. difﬁcile, where binding of MBL has
been shown to be low [24]. This suggests that MBL deﬁciency
does not per se predispose to CDI and is consistent with the ob-
served lack of difference in circulating concentrations of MBL be-
tween CDI cases and AAD controls. MBL has other functions
including modulation of inﬂammation and clearance of apopto-
tic cells [35]. The former may be relevant to CDI, where MBL
may be acting as a modulator of the disease. Consistent with
this, clinical manifestations of MBL deﬁciency appear to be of
more relevance either in infants when the immune system is
still maturing or in susceptible groups when there is an associated
immunodeﬁciency [36], such as in hospitalized elderly patients
Table 4. Analysis of Clostridium difﬁcile Infection Disease Outcomes Versus Serum Mannose-Binding Lectin Concentration Based on
Deﬁciency Cutoffs of 50 and 100 ng/mL
Concentration Cases (n = 308) Controls (n = 145) P Value OR (95% CI)
<50 ng/mL 41 (13%) 18 (12%) .79a 1.09 (.58–2.06)
<100 ng/mL 70 (23%) 23 (16%) .09b 1.61 (.93–2.79)
Death (n = 26) Survival (n = 276)
<50 ng/mL 3 (12%) 37 (13%) .78c 1.22 (.31–4.82)
<100 ng/mL 5 (19%) 64 (23%) .84c 0.88 (.27–2.89)
≥10 d (n = 174) <10 d (n = 113)
<50 ng/mL 27 (16%) 10 (9%) .10d 1.89 (.88–4.08)
<100 ng/mL 42 (24%) 22 (20%) .35d 1.32 (.74–2.35)
Recurrence (n = 81) Nonrecurrence (n = 136)
<50 ng/mL 18 (22%) 13 (10%) <.01e 3.18 (1.40–7.24)
<100 ng/mL 29 (36%) 24 (18%) <.01e 2.61 (1.35–5.04)
Severe (n = 125) Nonsevere (n = 180)
<50 ng/mL 16 (13%) 25 (14%) .78d 0.91 (.46–1.79)
<100 ng/mL 29 (23%) 41 (23%) .93d 1.02 (.60–1.76)
Data regarding duration of symptoms and disease recurrence was unavailable for 18 and 60 of our cases, respectively. For disease recurrence, an additional 28
patients had died within the follow-up period prior to experiencing any recurrent symptoms and therefore could not be included in the analysis. Serum mannose
binding lectin level was unavailable for an additional 3 individuals who were therefore excluded from analysis across all outcomes.
P values and ORs were calculated using univariate logistic regression and adjusted for the presence of significant covariates.
Abbreviations: CI, confidence interval; OR, odds ratio.
a Age, body mass index (BMI), time delay between testing positive and recruitment, and the presence of diabetes.
b Age, BMI, time delay between testing positive and recruitment, and the presence of diabetes and immunosuppressive therapy.
c Age, BMI, score on Charlson comorbidity index, and disease severity at baseline.
d No covariates were found to be significant and therefore P value remains unadjusted.
e Age.
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or following major clinical interventions. However, these are hy-
potheses that need further investigation.
Although MBL concentrations remain relatively constant in
individuals due to genetic determinants, MBL is known to be a
relatively modest acute phase reactant [37]. This is in sharp con-
trast to other acute phase proteins such as CRP whose concentra-
tions can increase sharply by 10- to 1000-fold during acute
inﬂammation [38]. Elevated CRP concentrations have previously
been shown to be associated with various CDI outcomes includ-
ing disease severity and recurrence [25, 39]. Consistent with this,
lowMBL concentrations have been associated with an increase in
the level of CRP [40], and with our ﬁndings of the association
with CDI recurrence and inverse correlation with CRP. In keep-
ing with the immunomodulatory effect of MBL, it is known that
low concentrations lead to increased secretion of the proinﬂam-
matory cytokines interleukin 6, interleukin 1β, and tumor necro-
sis factor α [40, 41], all of which have also been shown to be
elevated in response to CDI [42, 43].
The genetic architecture of the MBL2 gene is complex (Fig-
ure 1), with the existence of numerous common functional poly-
morphisms and haplotypes (Figure 1; Tables 2 and ;3; and
Supplementary Table 3). MBL2 haplotype frequencies and the
corresponding impact on serum MBL concentrations were in
line with those previously reported [9, 13] (Table 2). This was
also evident after stratiﬁcation of MBL haplotypes based on pre-
viously deﬁned expression genotypes [32, 33], with carriers of
low-expressing genotypes showing much lower serumMBL con-
centrations than both intermediate- and high-expressing geno-
types (32 ng/mL vs 190 ng/mL and 714 ng/mL, respectively;
Table 3). Despite the strong association observed between
MBL2 genotypes and serum MBL concentrations, and the asso-
ciation between MBL concentrations and CDI recurrence, there
was no association between MBL genotype and CDI outcomes.
Other studies have also identiﬁed associations with protein levels,
but not with genotype (Supplementary Table 1), highlighting the
need to evaluate both MBL genotype and phenotype in infection
and other immune conditions. The lack of association between
MBL genotype and disease outcome may be due to the incom-
plete genetic penetrance ofMBL genetic variation on phenotype.
In this study, only 78% and 68% of the low-expressing genotypes
accounted for deﬁcient serum levels using the cutoff values of
<50 ng/mL and <100 ng/mL, respectively (Supplementary
Table 4). Genetic heterogeneity due to functionally related
genes such as L-ﬁcolin, MASP2, and surfactant proteins may
also play a role, but this needs further investigation.
Our study sought to adhere to a stringent methodology
through the use of a relatively large cohort size and extensive
quality control, but it is not without its limitations. Although
there is less chance of MBL concentrations being confounded by
infection-related events compared with other response markers,
one of the clear drawbacks of this work is the lack of longitudinal
measurements, which is now being addressed in a new prospec-
tive study. The effect of proteins functionally related to MBL and
other markers of inﬂammation and the relative roles they play in
disease modulation need further investigation. Previous studies
have used various deﬁnitions for MBL deﬁciency, with common-
ly used cutoffs ranging from 50 ng/mL [30] to 500 ng/mL [32]. It
is thus difﬁcult to compare results across different study groups
given the heterogeneity of platforms, proﬁle of cohorts, and stan-
dards adopted for the measurement of MBL. Discrepancies be-
tween studies could be due to low sample sizes, poor assay
performance, and differences in techniques adopted by laborato-
ries. We have tried to overcome some of these limitations by eval-
uating a number of cutoff levels, but there is a need for
international consensus and harmonization in this area.
In conclusion, our data suggest that low serum MBL concen-
trations may act as a predictor of CDI recurrence. Further work
is needed to validate these ﬁndings in an independent cohort of
patients and to evaluate the mechanistic basis of this associa-
tion. This area of research would also be advanced through con-
sensus on deﬁnitions of deﬁciency, standardization of methods
employed for measurement of serum concentrations, and fur-
ther evaluation of the genotype–phenotype relationships.
Supplementary Data
Supplementary materials are available at Clinical Infectious Diseases online
(http://cid.oxfordjournals.org). Supplementary materials consist of data
provided by the author that are published to beneﬁt the reader. The posted
materials are not copyedited. The contents of all supplementary data are the
sole responsibility of the authors. Questions or messages regarding errors
should be addressed to the author.
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